**Appendix Table F146. Clinical outcomes after bulking agents (individual RCTs)**

| Reference sample | Active | Control | Definition of outcome | Randomized active/ control | Active events/ rate | Control events/ rate | Relative risk (95% CI) | Absolute risk differences (95% CI) | Number needed to treat (95% CI) | Attributable events/1000 treated (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Lightner, 2009[562] 344/0 | Zuidex Implacer | Contigen® Endoscopic guidance | Withdraw due to adverse events | 227/117 | 8/4 | 2/2 | 2.06 (0.44; 9.55) | 0.02 (-0.02; 0.05) | | |
| Lightner, 2009[562] 344/0 | Zuidex Implacer | Contigen® Endoscopic guidance | Lack of effect | 227/117 | 43/19 | 11/9 | 2.01 (1.08; 3.76) | 0.10 (0.02; 0.17) | 10 (6; 46) | 9 5 (22; 169) |
| Lightner, 2009[562] 344/0 | Zuidex Implacer | Contigen® Endoscopic guidance | Worsened incontinence at 12 months | 227/117 | 32/14 | 8/7 | 2.06 (0.98; 4.33) | 0.07 (0.01; 0.14) | 14 (7; 121) | 73 (8; 137) |
| Ghoniem, 2009[533] 247/0 | Transurethral injection of Macroplastique | Transurethral injection of Contigen® | Discontinued due to loss to followup | 122/125 | 20/16 | 31/25 | 0.66 (0.40; 1.09) | -0.08 (-0.18; 0.02) | | |
| Ghoniem, 2009[533] 247/0 | Transurethral injection of Macroplastique | Transurethral injection of Contigen® | Withdrew | 122/125 | 8/7 | 4/3 | 2.05 (0.63; 6.63) | 0.03 (-0.02; 0.09) | | |
| Ghoniem, 2009[533] 247/0 | Transurethral injection of Macroplastique | Transurethral injection of Contigen® | Physician assessment - unchanged | 122/125 | 6/5 | 10/8 | 0.61 (0.23; 1.64) | -0.03 (-0.09; 0.03) | | |
| Ghoniem, 2009[533] 247/0 | Transurethral injection of Macroplastique | Transurethral injection of Contigen® | Patient assessment - unchanged | 122/125 | 8/7 | 11/9 | 0.75 (0.31; 1.79) | -0.02 (-0.09 ;0.04) | | |
| Ghoniem, 2009[533] 247/0 | Transurethral injection of Macroplastique | Transurethral injection of Contigen® | Urge incontinence | 122/125 | 6/5 | 5/4 | 1.23 (0.39; 3.92) | 0.0 (-0.04; 0.06) | | |
| Strasser, 2007[598] 63/0 | Transurethral ultra-sonography-guided injections of autologous myoblasts and fibroblasts | Conventional endoscopic injections of collagen | Number of incontinent patients | 42/21 | 4/10 | 19/90 | 0.11 (0.04; 0.27) | -0.81 (-0.96; -0.66) | -1 (-2; -1) | -810 (-963; -656) |

**Appendix Table F146. Clinical outcomes after bulking agents (individual RCTs) (continued)**

| Reference sample | Active | Control | Definition of outcome | Randomized active/ control | Active events/ rate | Control events/ rate | Relative risk (95% CI) | Absolute risk differences (95% CI) | Number needed to treat (95% CI) | Attributable events/1000 treated (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Mayer, 2007[567] 296/0 | Calcium hydroxylapatite (CaHA) | Bovine Dermal Collagen | Urge incontinence after treatment | 158/138 | 7/5 | 12/9 | 0.51 (0.21; 1.26) | -0.04 (-0.10; 0.01) | | |
| Lightner, 2001[561] 364/0 | Injection of bulking agent 1.0 mL Durasphere max 5 times with a minimum 7-day interval | Injection of bulking agent bovine collagen max 5 times with a minimum 7-day interval | Incidence of urgency | 176/188 | 43/25 | 22/12 | 2.09 (1.30; 3.34) | 0.13 (0.05; 0.21) | 8 (5; 20) | 127 (49; 206) |